Published • loading... • Updated
What Is Moderna’s New Cancer Vaccine and How Big a Breakthrough Is It?
The personalised mRNA shot was paired with Keytruda and cut recurrence and spread risk in more than 1,000 patients, companies said.
Summary by Irish Times
5 Articles
5 Articles
Moderna and MSD announced the successful completion of Phase 3 clinical trials for Intismeran, a personalized cancer vaccine utilizing mRNA technology. The vaccine demonstrated efficacy in preventing recurrence and metastasis when administered in combination with Keytruda to melanoma patients. The company plans to expand research to various cancer types, including lung cancer, with the goal of launching the product in 2027.
The pharmaceutical companies Moderna and MSD have unveiled trial results with a cancer vaccine, which, according to a professor, promises good things for all of humanity's fight against the disease.
Coverage Details
Total News Sources5
Leaning Left3Leaning Right1Center0Last UpdatedBias Distribution75% Left
Bias Distribution
- 75% of the sources lean Left
75% Left
L 75%
R 25%
Factuality
To view factuality data please Upgrade to Premium
